HC Wainwright Predicts Precigen’s Q4 Earnings (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) – Investment analysts at HC Wainwright lifted their Q4 2026 earnings per share estimates for shares of Precigen in a report issued on Wednesday, August 5th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $0.06 per share for the quarter, up from their prior estimate of $0.04. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Precigen’s Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.10 EPS, Q3 2027 earnings at $0.12 EPS, Q4 2027 earnings at $0.14 EPS, FY2027 earnings at $0.44 EPS, FY2028 earnings at $0.71 EPS and FY2030 earnings at $1.49 EPS.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.06. Precigen had a positive return on equity of 484.64% and a negative net margin of 183.98%.The business had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. Precigen’s quarterly revenue was up 6322.7% compared to the same quarter last year.

PGEN has been the subject of several other research reports. Wall Street Zen cut shares of Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Finally, Citizens Jmp raised their price objective on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research note on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Precigen has a consensus rating of “Hold” and an average price target of $14.50.

Precigen Price Performance

Precigen stock opened at $6.89 on Thursday. The company has a market cap of $2.46 billion, a P/E ratio of -6.62 and a beta of 1.02. Precigen has a one year low of $1.70 and a one year high of $7.23. The business has a fifty day moving average of $5.12 and a two-hundred day moving average of $4.46. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82.

Hedge Funds Weigh In On Precigen

Institutional investors have recently made changes to their positions in the stock. State of Wyoming acquired a new stake in shares of Precigen during the first quarter valued at $27,000. NBC Securities Inc. acquired a new position in Precigen in the 4th quarter valued at about $38,000. Mason Investment Advisory Services Inc. acquired a new position in Precigen in the 4th quarter valued at about $42,000. Abel Hall LLC purchased a new position in Precigen in the 4th quarter valued at about $44,000. Finally, Royal Bank of Canada lifted its holdings in Precigen by 102.6% in the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,426 shares in the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Precigen

In related news, insider Donald P. Lehr sold 29,131 shares of Precigen stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total transaction of $127,011.16. Following the completion of the transaction, the insider directly owned 755,461 shares in the company, valued at $3,293,809.96. The trade was a 3.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Helen Sabzevari sold 346,836 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $5.89, for a total value of $2,042,864.04. Following the completion of the sale, the chief executive officer directly owned 3,768,872 shares in the company, valued at approximately $22,198,656.08. The trade was a 8.43% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 956,500 shares of company stock valued at $5,248,371 over the last three months. Company insiders own 41.40% of the company’s stock.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 results: Precigen reported $54.98 million in revenue, far above the roughly $28 million analyst estimate, and earnings of $0.05 per share versus expectations for a loss. Revenue increased more than 6,300% year over year, while PAPZIMEOS generated $53.1 million in quarterly net revenue. Precigen Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Commercial momentum and cash outlook: PAPZIMEOS patient-hub enrollment exceeded 500 patients, and the FDA granted the product seven years of market exclusivity. Precigen said product proceeds and its $38.7 million in cash, equivalents and investments are expected to support cash-flow break-even by the end of 2026. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: HC Wainwright raised its outlook: The firm reiterated a Buy rating and $18 price target while increasing EPS estimates for Q4 2026, every quarter of 2027, FY2027 to $0.44 from $0.34, and FY2030 to $1.49 from $1.44. The revisions indicate expectations for a faster transition to sustained profitability.
• Neutral Sentiment: Trading activity remains elevated: Precigen was reported to be the target of unusually large options activity, which may amplify short-term volatility without clearly indicating the direction of the stock.
• Negative Sentiment: Insider selling is a risk: Reported insider activity over the past six months consisted of sales only, including substantial selling by executives and major shareholder Randal J. Kirk. Such transactions may weigh on sentiment, although they do not necessarily reflect the company’s operating outlook.
• Negative Sentiment: One estimate was trimmed: HC Wainwright lowered its FY2028 EPS forecast slightly to $0.71 from $0.72, a modest offset to the broader upward revisions.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.